CEO James Sapirstein from ContraVir Pharmaceuticals (NASDAQ: CTRV) tells Proactive Investors they will save themselves 6-8 million dollars on the non clinical side by utilizing the 505(b)(2) Regulatory Pathway to streamline the development and registration of lead asset TXL for the treatment of Chronic Hepatitis B.
Meet Scancell Holdings Plc, Advanced Blast & Ballistic Systems Ltd and TokenCommunities Plc at our event, London, 08 March 2018.Register here >>